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patients. Surveillance for H1N1 requiring documented fever
will underestimate burden of disease. Children <5 years old
in Guatemala should be prioritized for vaccination.
doi:10.1016/j.ijid.2010.02.2202
65.005
Adjuvanted inﬂuenza vaccines and their potential role for
vaccination of travelers
T. Tsai 1,∗, N. Groth2, M. Pellegrini 2, D. O’Hagan1, A.
Hilbert3
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Background: Trivalent seasonal inﬂuenza vaccine (TIV)
adjuvanted with the emulsion adjuvant MF59® (FLUAD®)
is licensed in 29 countries worldwide for adults over 65
years of age. Compared with unadjuvanted TIV, the adju-
vanted vaccine provides higher hemagglutination inhibition
(HI) antibody titers not only against vaccine strains, but also
against drift-variant strains. Usually inﬂuenza is transmitted
in a single epidemic seasonal epidemic in temperate cli-
mates, but it may appear in two epidemics during the year
or may be transmitted throughout the year, in subtropical
and tropical locations. Although persons travelling from the
Northern Hemisphere (NH) to the tropics or antipodes may
not have access to the TIV made with strains used in the
Southern Hemisphere (SH) formulation, they are neverthe-
less recommended to receive available NH formulation-TIV
because one or more of the strains may overlap and because
some degree of protection may be elicited, even by an
imperfectly matched vaccine.
Methods: The following data from recent clinical
trials highlight the cross-protection elicited by the MF59-
adjuvanted vaccine. Sera from 222 children, 6-36 months of
age, vaccinated with the 2006/07 formulations of FLUAD or
unadjuvanted TIV were tested against the H1N1 strain in the
2007/08 formulation (A/Solomon Islands/3/2006 (H1N1)-
like). Sera from adults with chronic illnesses and elderly
adults (> 65 years) were similarly tested.
Results: In the children geometric mean titer (GMT) HI
responses, geometric mean ratios (GMR), and seroprotec-
tion (SP) rates were signiﬁcantly higher in FLUAD recipients.
Similar signiﬁcant differences were seen among 349 adults
with chronic illnesses with increased risk for inﬂuenza mor-
bidity who were vaccinated with either FLUAD or with an
undajuvanted subunit vaccine. Finally, 56 elderly adults who
received the 2007/08 FLUAD formulation displayed postvac-
cination responses against strains in the 2008/09 formulation
which met the European Committee for Human Medicinal
Products criteria for GMR, SP and SC for the mismatched
H1N1 and H3N2 strains.
Conclusion: Altogether these results suggest that the
greater degree of cross-variant immunity elicited by MF59-
adjuvanted inﬂuenza vaccine may offer an advantage in
circumstances where travelers may be exposed to antigeni-
cally mismatched viruses.
doi:10.1016/j.ijid.2010.02.2203
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Background: In late spring 2009, concern was raised in
anada that prior receipt of the 2008-09 trivalent inacti-
ated inﬂuenza vaccine (TIV) was associated with increased
isk of pandemic H1N1 (pH1N1) illness. Several epidemio-
ogic investigations were urgently conducted through the
ummer to assess this putative association.
Methods: Studies included: (1) test-negative case-control
esign based on Canada’s ongoing sentinel vaccine effective-
ess monitoring system in British Columbia, Alberta, Ontario
nd Quebec; (2) conventional case-control design using pop-
lation controls in Quebec; (3) testnegative case-control
esign in Ontario and (4) prospective household transmis-
ion (cohort) study in Quebec. Logistic regression estimated
dds ratios for TIV effect on community- or hospital-based
aboratory-conﬁrmed seasonal or pH1N1 inﬂuenza cases
ompared to controls with restriction, stratiﬁcation and
djustment for covariates including combinations of age,
ex, comorbidity, timeliness of medical visit, prior physician
isits, and/or health care worker status. For the prospective
tudy relative risks were computed.
Results: Based on the sentinel study of ∼700 cases and
00 controls, 2008-09 TIV provided statistically signiﬁcant
rotection against seasonal inﬂuenza (OR 0.44;95% CI 0.33-
.59). Conversely, estimates from the sentinel and several
ther study designs involving ∼1200 laboratory-conﬁrmed
H1N1 cases and 1500 controls consistently showed that
rior recipients of 2008-09 TIV were at statistically sig-
iﬁcant 1.5-2.5-fold increased risk of medically-attended
H1N1 illness during the spring/summer 2009 with upper
imit of the 95% conﬁdence interval spanning 3-4-fold
ncrease. There was non-signiﬁcant increase in the strength
f the association with more TIV doses received in the prior
ve years. Risk of pH1N1 hospitalization was not further
ncreased among vaccinated people when comparing hos-
italized to community cases.
Conclusion: Prior receipt of 2008-09 TIV was associ-
ted with increased risk of medicallyattended pH1N1 illness
uring the spring/summer 2009 in Canada. Possible biologi-
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al mechanisms and immuno-epidemiologic implications are
onsidered.
oi:10.1016/j.ijid.2010.02.2204
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onitoring for avian inﬂuenza in wild birds on the Far East
n 2008
. Sayfutdinova1,∗, J. Runstadler2, M. Kulak1, M. Sivay3
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Background: Waterbirds are natural reservoirs for low-
athogenic avian inﬂuenza and have been implicated as the
rimary source of infection in outbreaks of highly pathogenic
vian inﬂuenza. An understanding of the movements of birds
nd the ecology of avian inﬂuenza viruses within the wild
ird population is essential in assessing the risks to human
ealth and production industries. The purpose of this inves-
igation was surveillance for avian inﬂuenza in migratory
horebirds at the East Asian-Australasian Flyway. Sample
ollection was on Kamchatka, on the Kuril islands, at the
mursky region, on Sakhalin and on Chukchi Peninsula.
Methods: Viral RNA was isolated from virus-containing
llantoic ﬂuid with the RNeasy Mini kit (QIAGEN, Valencia,
A, USA) as speciﬁed by the manufacturer. Uni12 primer was
sed for reverse transcription. PCR was performed with a
et of primers speciﬁc for each gene segment of inﬂuenza
virus (18). PCR products were puriﬁed with the QIAquick
CR puriﬁcation or QIAquick gel extraction kit (QIAGEN). The
mplicons were sequenced on an automated Applied Biosys-
ems 3130 system using BigDye terminator cycle sequencing
eady reaction kit» (Applied BioSystems).
Results: In the Far East in the 2008 from birds
f 127 spices and 32 families were collected 4248
amples and 16 inﬂuenza viruses were isolated and
nalyzed. No highly pathogenic avian inﬂuenza viruses
ere identiﬁed. The hemagglutinin genes of stains
/Larus/Kamchatka/521/08(H13N6) isolated in Kamchatka
egion and A/Teal/Tinda/6114/08(H10N6) (bankit1288867 in
enebank) isolated in Amursky region were analyzed genet-
cally. The analysis shows homology with the strains which
ere isolated in the Astrahansky region and on Hokkaido
sland.
Conclusion: Surveillance activities for avian inﬂuenza in
ild birds should be continued to provide further epidemio-
ogical information about circulating viruses and to identify
ny changes in subtype prevalence.This work was supported by Russian Government and Bio
ndustry Initiative (BII) USA (ISTC#3436) and was done in
ollaboration with Novosibirsk State University.
oi:10.1016/j.ijid.2010.02.2205ternational Congress on Infectious Diseases (ICID) Abstracts
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Ministry of Public Health, Bangkok, Thailand
Background: On-going, comprehensive inﬂuenza surveil-
ance is critical to detect and monitor inﬂuenza outbreaks.
he Armed Forces Research Institute of Medical Sciences
AFRIMS) has established 45 inﬂuenza sentinel sites in
outh and Southeast Asia in 4 countries (Thailand, Nepal,
hilippines, Bhutan) and an additional 9 countries with par-
icipating US Embassies.
Methods: Patients who present with a history of fever
nd cough or sore throat can participate. Samples are tested
ith a rapid test for inﬂuenza A and B and realtime PCR for
nﬂuenza A (H1, pH1, H3, H5) and B. Some positive samples
ndergo virus isolation, characterization and sequencing at
FRIMS or in the US at the Centers for Disease Control and
revention (WHO Collaborating Center for Surveillance, Epi-
emiology and Control of Inﬂuenza).
Results: From October 2005 through September 2009,
FRIMS sites collected samples from 7,713 patients with
,239 taken since the H1N1 outbreak started in May 2009.
or the entire surveillance period, 42.2% of the samples
ere positive for inﬂuenza A or B by PCR. Since June 2009,
9.1% of the positive inﬂuenza samples have been pH1N1
ositive. Our surveillance system was the ﬁrst to detect
he presence of pH1N1 in Nepal and Bhutan. Evaluation of
nﬂuenza rapid tests compared to PCR differed by site but
ad overall 60% sensitivity and 97% speciﬁcity, and pH1N1
ad a 68% sensitivity and 98% speciﬁcity. Sequences from
ecent seasonal H1N1 viruses demonstrated greater than 97%
omology at the amino acid level with the 08/09 H1N1 vac-
ine strain. Samples from Bhutan and the Philippines had a
ery similar strain in circulation with 98.9-99.6% homology
t the amino acid level. A/Nepal/NP06C-017/2008 showed
he greatest divergence with the other strains (96.6-97.5%
omology). Seven pandemic H1N1 HA genes were sequenced
nd compared to other circulating viruses and were very sim-
lar. To date, all seasonal H1N1 and H3N2 viruses that have
een screened have genetic markers for M2 blocker resis-
ance and all pH1N1 demonstrate NA inhibitor resistance.
